2585-23-1Relevant articles and documents
Trifluoroacetic Acid Hydroxylamine System as Organocatalyst Reagent in a One-Pot Salt Free Process for the Synthesis of Caprolactam and Amides of Industrial Interest
Manente,Pietrobon,Ronchin,Vavasori
, p. 3543 - 3549 (2021/03/30)
In this work we studied the reactivity of the Trifluoroacetic acid hydroxylamine system in the one step salt free synthesis of amides from ketones. A particular regards was paid to the caprolactam synthesis because of its industrial relevance. Synthesis, reactivity and characterization of the hydroxylamine trifluoroacetate is given. Fast oximation reaction of several ketones was gained at room temperature (1?h of reaction quantitative conversion for several ketones). In the same reactor, by raising the temperature at 383?K, the Beckmann rearrangement of the so obtained oximes is easily accomplished in the presence of three equivalent of TFA. The possibility of obtaining the trifluoroacetate of the hydroxylamine with a modified nitric acid hydrogenation reactions was verified, too. Reuse of solvent and trifluoroacetic acid is easily achieved by distillation. Graphical abstract: Salt free one-pot caprolactam and amides process catalyzed by CF3COOH, in the presence of NH2OH TFA as the oximation agent.[Figure not available: see fulltext.].
2-(4-methanoyl) anilino-4-aminopyrimidine derivatives and application thereof
-
Paragraph 0031-0036, (2021/04/03)
The invention belongs to the technical field of chemical medicines, and particularly relates to 2-(4-methanoyl) anilino-4-aminopyrimidine derivatives and application thereof. According to the invention, nitryl, carboxyl, cyano and the like are adopted to
4, 6-disubstituted pyridine [3, 2-d] pyrimidine compound as well as preparation and application thereof
-
Paragraph 0403-0406, (2020/04/02)
The invention belongs to the technical field of medicines. The invention relates to the field of pharmaceutical chemistry, in particular to a 4, 6-disubstituted pyridine [3, 2-d] pyrimidine compound and pharmaceutically acceptable salt thereof, a preparation method of the compound, a pharmaceutical composition taking the compound as an active ingredient, and application of the compound in preparation of an MNK inhibitor and drugs for treating and/or preventing various cancers and/or metabolic diseases. The present invention relates to compounds represented by formulas I, II, III or IV, and pharmaceutically acceptable salts, hydrates, solvates and metabolites thereof, wherein the variables are described in the claims and the description.